Translate Bio Inc (NASDAQ:TBIO) has been given an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 1 year consensus price objective of $22.75 for the company and are expecting that the company will post ($0.44) EPS for the current quarter, according to Zacks. Zacks has also assigned Translate Bio an industry rank of 84 out of 255 based on the ratings given to its competitors.
A number of research analysts have recently commented on the company. HC Wainwright assumed coverage on Translate Bio in a research report on Monday, December 24th. They set a “buy” rating and a $21.00 price target on the stock. ValuEngine downgraded shares of Translate Bio from a “buy” rating to a “hold” rating in a report on Friday, December 21st.
NASDAQ:TBIO traded up $0.17 during trading hours on Monday, hitting $13.12. 191,765 shares of the company were exchanged, compared to its average volume of 194,874. The firm has a market cap of $586.29 million and a P/E ratio of -3.60. Translate Bio has a one year low of $4.81 and a one year high of $16.60. The company has a quick ratio of 10.47, a current ratio of 10.47 and a debt-to-equity ratio of 0.83.
Translate Bio (NASDAQ:TBIO) last issued its earnings results on Thursday, March 21st. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.09. The firm had revenue of $1.18 million during the quarter, compared to analyst estimates of $0.80 million. As a group, equities research analysts expect that Translate Bio will post -1.52 EPS for the current year.
Translate Bio Company Profile
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.